644.8. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lympho-cyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by theGerman Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109-111.9. Advani RH, Horning SJ, Hoppe RT, et al. Frontline therapy of nodularlymphocyte predominant Hodgkin lymphoma with rituximab: the StanfordUniversi...

Histologic transformation of follicular lymphoma to an aggressive non-Hodgkin lymphoma is a critical biologic event with profound implications on the natural history of this otherwise indolent disease. Recent insights into the genetic and epigenetic basis of transformation have been described, with the recognition of pivotal events governing the initiation and persistence of tumor evolution. Ou...

BACKGROUND Epstein-Barr virus plays an important role in pathogenesis of Hodgkin lymphoma. The first patient with Epstein-Barr positive Reed Sternberg cells was described in 1985. Since then association between Epstein-Barr virus and Hodgkin lymphoma has been shown in many parts of the world and its occurrence shows significant variation from continent to continent and from country to country. ...

[as found here: http://www.medicalgeo.com/Med-Diseases-L/Lymphoma.html] Lymphoma A general term for malignancies of lymphocytes or, more rarely, of histiocytes. Collectively, these cell types non hodgkins lymphoma symptoms of form the reticuloendothelial system and circulate in the vessels of the lymphatic system. Traditionally, Lymphoma is classified lymphoma cancer as Hodgkin's lymphoma, disc...

Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associated with liver dysfunction, but no cases of cholestatic hepatitis C were described. To our knowledge, this is the first case of cholestatic hepatitis...

Human immunodeficiency virus (HIV) chronically infected patients are at increased risk of developing non-Hodgkin lymphoma compared with the general population. Highly active antiretroviral therapy has had a dramatic effect on the natural history of HIV infection, reducing the incidence of acquired immunodeficiency syndrome-related non-Hodgkin lymphoma and improving overall survival. However, pr...

Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma. After the (11;14) translocation was identified as its constant finding in 1992, MCL was recognized as a separate subgroup of non-Hodgkin lymphoma (NHL). In MCL, extranodal involvement may be observed in the bone marrow, the spleen, the liver, and the gastrointestinal system (GIS). Cases of MCL that present with a massive and so...

Background: The gastrointestinal tract is the most common site of extranodal Non-Hodgkin lymphoma, accounting for 20% to 40% all lymphomas. This study aims accomplish objective: classify prevalent histopathological patterns lymphoma according WHO 2019 classification based on histopathology and immunohistochemistry. Subjects methods: A cross-sectional sampled 76 patients be examined treated at H...

T-cell non-Hodgkin lymphomas (NHLs) are uncommon malignancies. The current WHO/EORTC classification recognizes 9 distinct clinicopathologic peripheral T-cell NHLs. These disorders have unique characteristics and require individualized diagnostic and therapeutic strategies. Tremendous progress has been made in recent years in the understanding of the pathogenesis of these disorders. Specific chr...

BACKGROUND Non-Hodgkin lymphoma (NHLs) are a heterogeneous group of lymphoid neoplasms, characterized by an irregular pattern of spread and may present with extranodal involvement This study was conducted to determine the frequency and pattern of Bone marrow involvement on trephine biopsy in cases of Non-Hodgkin lymphoma (NHL). METHODS This cross sectional study was conducted in Pathology dep...